Definium Therapeutics (DFTX) Liabilities and Shareholders Equity (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $401.3 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 45.75% year-over-year to $401.3 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 15.27% increase from a year earlier, with the FY2025 full-year figure at $440.1 million, up 45.66% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $401.3 million, down from $440.1 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for DFTX reached as high as $440.1 million in Q4 2025 and fell as low as $124.5 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $234.3 million across 5 years, with a median of $236.9 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity dropped 26.74% in 2023 and soared 142.61% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $170.0 million in 2022, then decreased by 26.74% to $124.5 million in 2023, then jumped by 142.61% to $302.2 million in 2024, then soared by 45.66% to $440.1 million in 2025, then fell by 8.82% to $401.3 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $401.3 million in Q1 2026, $440.1 million in Q4 2025, and $236.9 million in Q3 2025.